PERTENTANGAN PEMBERIAN PERLINDUNGAN HAK PATEN TERHADAP INVENSI PENGGUNAAN TEKNOLOGI CRISPR-Cas9 PADA GEN MANUSIA

Article Sidebar

ARTICLE PDF
Published: Jun 26, 2023
DOI: https://doi.org/10.31933/unesrev.v5i4.532

Main Article Content

Ida Nur Azizah
Fakultas Hukum, Universitas Indonesia, Jakarta, Indonesia

Abstract

The TRIP’S Agreement confirms that Member States may exclude certain types of inventions from patentability and may refuse to grant patents on methodological inventions used on humans, including the granting of patents on inventions in the field of biotechnology applied to humans. Indonesia regulates patent protection for biotechnology in the Patent Law, which emphasizes that patents cannot be granted for inventions of biotechnological processes applied to humans. However, with the development of technology, the use of inventions in the field of biotechnology applied to human genes is considered to have great benefits for mankind. Therefore, this research that uses doctrinal-normative methodology through a statute approach will discuss how the TRIP’s Agreement and the Patent Law in Indonesia regulate patents on biotechnology products applied to human genes and the urgency of granting patent protection to biotechnology inventions applied to humans so that it can be known that granting patents to biotechnology inventions applied to humans is prohibited by Indonesian law but given freedom under international law and further research and comprehensive studies need to be done to deal with future trade liberalization flows.

Downloads

Download data is not yet available.

Article Details

How to Cite
Nur Azizah, I. (2023). PERTENTANGAN PEMBERIAN PERLINDUNGAN HAK PATEN TERHADAP INVENSI PENGGUNAAN TEKNOLOGI CRISPR-Cas9 PADA GEN MANUSIA. UNES Law Review, 5(4), 3001-3014. https://doi.org/10.31933/unesrev.v5i4.532
Issue
Vol. 5 No. 4 (2023): UNES LAW REVIEW (Juni 2023)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Hak cipta :

Penulis yang mempublikasikan manuskripnya di jurnal ini menyetujui ketentuan berikut:

  1. Hak cipta pada setiap artikel adalah milik penulis.
  2. Penulis mengakui bahwa UNES Law Review berhak menjadi yang pertama menerbitkan dengan lisensi Creative Commons Attribution 4.0 International (Attribution 4.0 International CC BY 4.0) .
  3. Penulis dapat mengirimkan artikel secara terpisah, mengatur distribusi non-eksklusif manuskrip yang telah diterbitkan dalam jurnal ini ke versi lain (misalnya, dikirim ke repositori institusi penulis, publikasi ke dalam buku, dll.), dengan mengakui bahwa manuskrip telah diterbitkan pertama kali di Jurnal UNES Law Review.

References

Cohen, Joe, The Latest round in the CRISPR patent battle has an apparent victor, but the fight continues, 11 September 2020, tersedia pada https://www.science.org/content/article/latest-round-crispr-patent-battle-has-apparent-victor-fight-continues, diakses pada 21 Mei 2023.
Correa, Carlos, ed., Access to Medicines and Vaccines: Implementing Flexibilities Under Intellectual Property Law, Cham: Springer Nature, 2022.
D’Amato, Anthony, dan Doris Long, International Intellectual Property Law, London: Kluwer Law Internasional 1997.
Febrina, M., & Massie, M. A. P, Implementasi CRISPR-Cas9 pada Manusia: Risiko dan Perdebatannya, 22 Februari 2020 tersedia pada https://www.balairungpress.com/2020/02/implementasi-crispr-cas9-pada-manusia-risiko-dan-perdebatannya, diakses pada tanggal 20 Mei 2023.
Harper, Joyce, dan Gerald Schatten, Are we ready for genome editing in human embryos for clincal purposes?, European Journal of Medical Genetics, Vol. 62, Issue 8, (2019).
Haugen, Hans, Human Rights and TRIPS Exclusion and Exception Provisions, The Journal of World Intellectual Property, Vol. 11, no. 5/6, (2009).
Henderson, Hope, CRISPR Clinical Trials: A 2022 Update, 29 Maret 2022, tersedia pada https://innovativegenomics.org/news/crispr-clinical-trials-2022/, diakses pada tanggal 29 Mei 2023.
Ibrahim, Johnny, Teori dan Metode Penelitian Hukum Normatif, Malang: Bayumedia, 2006.
Kementerian Hukum dan Hak Asasi Manusia, Laporan Tahunan Direktorat Jenderal Kekayaan Intelektual 2021, (Jakarta, DJKI Kemenkumham, 2021).
Kementerian Kesehatan, Angka Pembawa Sifat Talasemia Tergolong Tinggi, 20 Mei 2019, tersedia pada https://www.kemkes.go.id/article/view/19052100003/angka-pembawa-sifat-talasemia-tergolong-tinggi.html, diakses pada tanggal 21 Mei 2023.
Marzuki, Peter, Penelitian Hukum Edisi Revisi, Jakarta: Prenadamedia Group, 2019.
Regalado, Antonio, The creator of the CRISPR babies has been released from a Chinese prison, 4 April 2022, tersedia pada https://www.technologyreview.com/2022/04/04/1048829/he-jiankui-prison-free-crispr-babies/, diakses pada tanggal 25 Mei 2023.
Sardjono, Agus, Patent, Technology, And The Role of University, Indonesia Law Review, Vol. 1, No.1, (2013).
WIPO, Patents: What is a Patent?, tersedia pada https://www.wipo.int/patents/en/, diakses pada tanggal 20 Mei 2023.
You, Lu, et. al, Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer, Nature Medicine, Vol. 26, hlm. 8.